These types of BRCA1/2 negative cancers are naturally sensitive to PARP inhibitors (Bryant et al., 2005; Farmer et al., 2005; Liu et al., 2008; Rottenberg et al., 2008; Fong et al., 2009; Evers et al., 2010). Here, BRCA1 is linked to cancer.